CJC-1295 Without DAC 5mg + Ipamorelin 5mg Blend — SEO Product Content

SEO Title

CJC-1295 Without DAC 5mg + Ipamorelin 5mg | GH Research Blend

SEO Meta Description

CJC-1295 without DAC 5mg + Ipamorelin 5mg research blend for laboratory studies of growth hormone signaling, GHRH, GH secretion and the GH-IGF-1 axis.

Suggested URL Slug

/product/cjc-1295-without-dac-5mg-ipamorelin-5mg-blend/

CJC-1295 Without DAC 5mg + Ipamorelin 5mg Blend

CJC-1295 Without DAC + Ipamorelin Research Blend

CJC-1295 Without DAC 5mg + Ipamorelin 5mg Blend combines two experimentally studied compounds associated with the regulation of growth hormone (GH) secretion.

Each vial contains:

• CJC-1295 without DAC — 5mg
• Ipamorelin — 5mg
• Total peptide content — 10mg

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analogue, while ipamorelin is a selective growth hormone secretagogue associated with the GHS receptor/GHSR pathway.

These compounds therefore provide two distinct experimental approaches to studying the somatotropic or GH-IGF-1 axis.

Pure Axis Peptides offers this formulation as research material for qualified laboratory and scientific investigations.

What Is the CJC-1295 Without DAC + Ipamorelin Blend?

This two-component formulation combines:

CJC-1295 without DAC

→ GHRH-related signaling

and

Ipamorelin

→ growth-hormone-secretagogue signaling

The resulting research model can be used to investigate interactions between different upstream pathways involved in pituitary GH secretion.

The formulation contains:

5mg CJC-1295 without DAC + 5mg Ipamorelin = 10mg total peptide content.

The 5mg + 5mg quantity is a product specification, not a recommended human dosage or established treatment protocol.

What Is CJC-1295 Without DAC?

CJC-1295 is a synthetic analogue derived from the structure of growth hormone-releasing hormone.

GHRH is the endogenous hypothalamic hormone responsible for stimulating GH production and secretion from pituitary somatotrophs.

CJC-1295 research has demonstrated the ability of GHRH-analogue signaling to increase GH and IGF-1 concentrations. Human studies of long-acting CJC-1295 have demonstrated sustained increases in GH and IGF-1, although those studies concern long-acting CJC-1295 rather than establishing clinical effects for every formulation marketed as “CJC-1295 without DAC.”

For accurate product identification, the without-DAC formulation should be distinguished from CJC-1295 with DAC.

CJC-1295 Without DAC vs. CJC-1295 With DAC

This is an important distinction for both SEO and scientific accuracy.

CJC-1295 Without DAC

Generally refers to a CJC-1295/GHRH analogue formulation without the Drug Affinity Complex (DAC) modification responsible for prolonged albumin binding.

CJC-1295 With DAC

The DAC modification was designed to increase circulation time through albumin binding.

Research on CJC-1295 with DAC demonstrated prolonged pharmacokinetic activity and sustained increases in GH and IGF-1.

Therefore, the two products should not be presented as interchangeable.

Explore CJC-1295 With DAC for the long-acting formulation.

Explore CJC-1295 Without DAC for the individual non-DAC research product.

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide and growth hormone secretagogue.

Experimental pharmacological research characterized ipamorelin as a selective GH secretagogue acting through a GHRP-like receptor. In animal and cellular models, it stimulated GH release while showing considerably less effect on ACTH and cortisol than some earlier secretagogues.

This makes ipamorelin particularly relevant to research involving:

• Growth hormone secretion
• GHSR signaling
• Pituitary somatotrophs
• GH pulsatility
• GH-IGF-1 axis biology
• Growth hormone secretagogue pharmacology

CJC-1295 and GHRH Research

Growth hormone-releasing hormone (GHRH) is an endogenous hypothalamic signal that stimulates pituitary GH secretion.

The basic physiological pathway can be represented as:

Hypothalamus → GHRH → Pituitary somatotroph → GH

CJC-1295 was developed as a synthetic GHRH analogue capable of activating the GHRH receptor.

Experimental studies have demonstrated that CJC-1295 can increase GH secretion and subsequently increase IGF-1 levels.

Ipamorelin and Growth Hormone Secretagogue Research

Ipamorelin belongs to the broader class of growth hormone secretagogues (GHSs).

Research indicates that ipamorelin stimulates GH release through a GHRP-like receptor pathway rather than directly mimicking GHRH.

This gives the two components of the blend different pharmacological starting points.

CJC-1295

GHRH receptor pathway

Ipamorelin

GHS receptor pathway

This distinction is central to understanding the scientific rationale behind the formulation.

CJC-1295 + Ipamorelin and the GH Axis

The growth hormone axis involves multiple interacting signals.

A simplified model is:

GHRH → GHRH receptor → GH secretion

while:

Ghrelin/GHSR-related signaling → GH secretagogue pathway → GH secretion

CJC-1295 and ipamorelin therefore provide researchers with two different experimental tools for investigating GH release.

The blend can be used conceptually to study interactions between:

• GHRH signaling
• GHSR signaling
• Pituitary GH secretion
• GH pulsatility
• IGF-1 production
• Endocrine feedback

CJC-1295 + Ipamorelin and Growth Hormone Research

Growth hormone is secreted naturally in pulses rather than at a constant rate.

Research has shown that GHRH-related stimulation can influence GH secretion while preserving aspects of pulsatile secretion. Human research with long-acting CJC-1295 found increased GH secretion with preserved GH pulsatility.

Ipamorelin research similarly provides a model for studying pharmacological stimulation of GH secretion.

Potential research endpoints include:

• GH concentration
• GH pulse amplitude
• GH pulse frequency
• Mean GH levels
• Basal GH levels
• IGF-1
• IGFBP-3
• Pituitary signaling

CJC-1295 + Ipamorelin and IGF-1 Research

Insulin-like growth factor-1 (IGF-1) is a major downstream component of the GH axis.

A simplified pathway is:

GHRH/GHSR signaling → GH → IGF-1

Human research with CJC-1295 demonstrated increases in circulating IGF-1 following administration of the long-acting analogue.

This makes IGF-1 an important research endpoint for studies examining GH-axis modulation.

CJC-1295 + Ipamorelin and Pituitary Research

The anterior pituitary contains specialized somatotroph cells responsible for GH production and secretion.

GHRH acts directly on these cells through the GHRH receptor.

Growth hormone secretagogues such as ipamorelin stimulate GH release through a separate receptor system.

This makes the combination particularly relevant to research examining:

• Somatotroph physiology
• GHRH receptor signaling
• GHSR signaling
• GH synthesis
• GH secretion
• Endocrine feedback

CJC-1295 + Ipamorelin and GHRH Signaling

CJC-1295 belongs to the GHRH-analogue research family.

GHRH signaling can influence:

• GH synthesis
• GH secretion
• Somatotroph activity
• IGF-1 production
• Endocrine feedback

The CJC-1295 molecule was originally identified from modified hGRF(1-29) derivatives designed to improve stability and activity.

Ipamorelin and GHSR Signaling

Ipamorelin is associated with the growth hormone secretagogue receptor (GHSR) pathway.

Experimental research found that ipamorelin stimulated GH release through a GHRP-like receptor and displayed a relatively selective GH-secretagogue profile in the tested models.

This provides a distinct signaling route from the GHRH receptor.

CJC-1295 + Ipamorelin: Complementary Pathways

The primary scientific rationale for studying these compounds together is their different points of action.

CJC-1295

GHRH analogue → GHRH receptor → pituitary GH signaling

Ipamorelin

GHS → GHSR → pituitary GH release

The combination can therefore be investigated as a model of dual-pathway GH secretagogue research.

However, this mechanistic rationale should not be interpreted as proof that the combination is synergistic or clinically superior to either compound alone.

Is CJC-1295 + Ipamorelin Synergistic?

The word “synergy” should be used cautiously.

Although CJC-1295 and ipamorelin act through different upstream pathways, the existence of two pathways does not automatically demonstrate synergistic activity.

A proper synergy claim would require controlled experiments comparing:

• CJC-1295 alone
• Ipamorelin alone
• CJC-1295 + Ipamorelin
• Appropriate control

Therefore, Pure Axis should describe this product as a dual-pathway GH research blend, rather than claiming clinically proven synergy.

CJC-1295 + Ipamorelin vs. CJC-1295 Alone

CJC-1295 Alone

Provides an experimental model focused primarily on GHRH-related signaling.

CJC-1295 + Ipamorelin

Provides a two-component model involving both:

• GHRH-related signaling
• GHSR-related signaling

This can be useful for comparative laboratory research examining whether simultaneous stimulation produces different endocrine responses from either pathway independently.

CJC-1295 + Ipamorelin vs. Ipamorelin Alone

Ipamorelin Alone

Provides an experimental model of selective growth hormone secretagogue activity.

CJC-1295 + Ipamorelin

Adds a GHRH-analogue component to the GHSR pathway.

This creates a research framework for studying the interaction between two different mechanisms regulating GH secretion.

CJC-1295 + Ipamorelin vs. HGH 191AA

The distinction between this blend and full-length HGH 191AA is important.

CJC-1295 + Ipamorelin

→ stimulates endogenous GH secretion pathways

HGH 191AA / Somatropin

→ provides the complete GH protein and acts directly through the growth hormone receptor

Explore HGH 191AA (Somatropin) for full-length recombinant human growth hormone research.

CJC-1295 + Ipamorelin vs. Sermorelin

Sermorelin is a GHRH analogue representing another approach to studying the GHRH pathway.

The key distinction is:

Sermorelin → GHRH receptor

CJC-1295 → GHRH receptor

Ipamorelin → GHSR

This makes the blend relevant to comparative research involving different methods of influencing GH secretion.

Explore Sermorelin for related GHRH research.

CJC-1295 + Ipamorelin vs. GHRP-2

GHRP-2 is another growth hormone secretagogue.

Both GHRP-2 and ipamorelin belong to the broader GH-secretagogue research category, but they have different pharmacological profiles.

Explore GHRP-2 Acetate for comparative GH-secretagogue research.

CJC-1295 + Ipamorelin vs. GHRP-6

GHRP-6 is another experimental GH secretagogue.

Ipamorelin was specifically developed as a selective GH secretagogue, and early pharmacological research compared its GH-releasing activity with GHRP-6.

Explore GHRP-6 Acetate for related research.

CJC-1295 + Ipamorelin and GH-IGF-1 Axis Research

The GH-IGF-1 axis is one of the strongest scientific themes for this product.

Research may examine:

• GH
• IGF-1
• IGFBP-3
• GHRH
• GHSR
• GHRH receptor
• Somatostatin
• Pituitary signaling
• Endocrine feedback

This creates a strong topical SEO relationship between the product and the wider growth-hormone research category.

CJC-1295 + Ipamorelin and Endocrine Feedback

GH secretion is regulated by several interacting hormones.

Important components include:

• GHRH
• Somatostatin
• Ghrelin-related signaling
• GH
• IGF-1

IGF-1 participates in feedback regulation of the GH axis.

Researchers can therefore use the CJC-1295 + ipamorelin model to investigate how multiple upstream signals affect downstream endocrine responses.

CJC-1295 + Ipamorelin and GH Pulsatility

Physiological GH secretion is pulsatile.

Research involving CJC-1295 has demonstrated increased GH secretion while preserving aspects of pulsatile GH release in human subjects.

Ipamorelin provides another experimental tool for investigating GH-secretagogue effects.

Potential endpoints include:

• Pulse frequency
• Pulse amplitude
• Basal GH
• Peak GH
• Mean GH
• IGF-1

CJC-1295 + Ipamorelin Research Applications

The blend may be relevant to laboratory studies involving:

Growth Hormone Research: Investigating mechanisms controlling GH secretion.

GHRH Research: Studying GHRH receptor signaling.

GHSR Research: Investigating growth hormone secretagogue receptor biology.

Pituitary Research: Studying somatotroph function.

GH Pulsatility Research: Examining patterns of hormone secretion.

IGF-1 Research: Investigating downstream GH signaling.

Endocrine Research: Studying hypothalamic-pituitary regulation.

Receptor Pharmacology: Comparing GHRH and GHSR pathways.

Secretagogue Research: Comparing different GH-releasing compounds.

GH-IGF-1 Axis Research: Investigating interactions between GH and IGF-1.

Protein Signaling Research: Studying endocrine receptor pathways.

Comparative Pharmacology: Evaluating individual versus combined pathway stimulation.

CJC-1295 Without DAC 5mg + Ipamorelin 5mg Formulation

Each vial contains:

CJC-1295 without DAC — 5mg

Ipamorelin — 5mg

Total peptide content — 10mg

The 5mg + 5mg composition is a formulation specification, not a recommended dose or clinical treatment protocol.

Researchers should document the exact formulation, batch number, purity and certificate of analysis when using the material experimentally.

Analytical Considerations

Because the product contains two distinct peptides, researchers should verify:

• CJC-1295 identity
• Confirmation of the non-DAC formulation
• Ipamorelin identity
• Individual peptide purity
• Total peptide content
• Formulation characteristics
• Batch number
• Storage requirements
• Certificate of analysis

This is particularly important because CJC-1295 with DAC and without DAC are distinct formulations with materially different pharmacokinetic properties.

Research Evidence and Limitations

The underlying biology of CJC-1295 and ipamorelin has been investigated experimentally.

Human studies of long-acting CJC-1295 demonstrated sustained increases in GH and IGF-1, while early pharmacological studies characterized ipamorelin as a selective GH secretagogue.

However, these studies should not be interpreted as clinical validation of this specific 5mg CJC-1295 without DAC + 5mg ipamorelin formulation.

Research on peptide products sold through unregulated channels also faces uncertainty around composition, purity and formulation. A recent review highlights the limited evidence base surrounding several GH-axis research compounds and the distinction between experimental research and approved clinical uses.

Explore Related Research

The CJC-1295 Without DAC + Ipamorelin Blend fits naturally into Pure Axis Peptides’ growth-hormone-axis research cluster.

Explore CJC-1295 Without DAC for the individual GHRH analogue.

Explore CJC-1295 With DAC for the long-acting DAC formulation.

Explore Ipamorelin for individual GH-secretagogue research.

Explore Sermorelin for related GHRH research.

Explore GHRP-2 Acetate for comparative secretagogue research.

Explore GHRP-6 Acetate for additional GHS research.

Explore HGH 191AA (Somatropin) for full-length human growth hormone research.

Browse the Peptides collection for additional research materials.

Visit Shop All Products for the complete Pure Axis Peptides catalog.

Research Use Only

CJC-1295 Without DAC 5mg + Ipamorelin 5mg Blend supplied by Pure Axis Peptides is intended strictly for laboratory and scientific research. It is not intended for human consumption, self-administration, diagnosis, treatment, cure, or prevention of any disease or medical condition. CJC-1295 and ipamorelin are biologically active experimental compounds, and research findings should not be interpreted as establishing this specific combination as an approved therapeutic product or clinically proven treatment. The 5mg + 5mg formulation is a product specification and not a recommended human dosage. Researchers should evaluate all materials according to their experimental requirements, product documentation and applicable laboratory procedures.

Internal Linking Recommendations

Primary Internal Links

• CJC-1295 Without DAC → https://pureaxispeptides.com/product/cjc-1295-without-dac/
• CJC-1295 With DAC → https://pureaxispeptides.com/product/cjc-1295-with-dac/
• Ipamorelin → https://pureaxispeptides.com/product/ipamorelin/
• Sermorelin → https://pureaxispeptides.com/product/sermorelin/
• GHRP-2 Acetate → https://pureaxispeptides.com/product/ghrp-2-acetate/
• GHRP-6 Acetate → https://pureaxispeptides.com/product/ghrp-6-acetate/
• HGH 191AA → verify current live product URL
• Peptides → https://pureaxispeptides.com/product-category/peptides/
• Shop All Products → https://pureaxispeptides.com/shop/

Verify exact live WooCommerce URLs before publishing.

Recommended Internal-Link Anchors

Use varied contextual anchors such as:

• “CJC-1295 without DAC + Ipamorelin blend”
• “CJC-1295 5mg + Ipamorelin 5mg”
• “CJC-1295 Ipamorelin research blend”
• “GH research peptide blend”
• “growth hormone research”
• “GH secretagogue research”
• “GHRH research”
• “GHSR research”
• “GH-IGF-1 axis research”
• “growth hormone signaling”
• “pituitary GH research”
• “GH pulsatility research”

Recommended Site Architecture

Build a dedicated GH-axis topical cluster:

CJC-1295 + Ipamorelin Blend
→ CJC-1295 Without DAC
→ CJC-1295 With DAC
→ Ipamorelin
→ Sermorelin
→ GHRP-2
→ GHRP-6
→ HGH 191AA
→ HGH Fragment 176-191
→ GHRH
→ GHSR
→ GH
→ IGF-1

Recommended Supporting Articles

“CJC-1295 Without DAC vs With DAC: Understanding the Difference”

“CJC-1295 vs Ipamorelin: Comparing Two Growth Hormone Signaling Pathways”

“CJC-1295 + Ipamorelin: What Does the Research Actually Show?”

“GH Secretagogues Explained: CJC-1295, Ipamorelin, GHRP-2 and GHRP-6”

These articles can capture informational searches and create internal authority around the product cluster without relying on unsupported performance or medical claims.

External Scientific References

• PubMed — CJC-1295 and GH/IGF-1 Secretion
• PubMed — CJC-1295 and GH Pulsatility
• PubMed — CJC-1295 as a GHRH Analogue
• PubMed — Ipamorelin, the Selective Growth Hormone Secretagogue
• PubMed — GH/IGF-1 Axis and CJC-1295

Product Tags

CJC-1295 Ipamorelin Blend, CJC-1295 Without DAC 5mg, Ipamorelin 5mg, CJC-1295 5mg Ipamorelin 5mg, CJC-1295 Without DAC Ipamorelin, CJC-1295 + Ipamorelin, CJC-1295 Ipamorelin Research, CJC-1295 Research Blend, Ipamorelin Research Blend, GH Research Peptide, Growth Hormone Research, Growth Hormone Secretagogue, GH Secretagogue Research, GHRH Research, GHSR Research, GH-IGF-1 Axis, IGF-1 Research, Growth Hormone Signaling, Growth Hormone Secretion, GH Pulsatility, Pituitary Research, Somatotroph Research, Endocrine Research, Reproductive Endocrinology Research, GHRH Analogue, GHRH Analog, CJC-1295 Research, CJC-1295 Without DAC Research, Ipamorelin Research, Peptide Research, Research Peptide Blend, Experimental Peptide, Laboratory Research